Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects

This study has been completed.
Yale University
Information provided by (Responsible Party):
Pfizer Identifier:
First received: May 11, 2011
Last updated: December 21, 2012
Last verified: December 2012
This study aims to determine whether the drug affects brain activity in healthy volunteers, either when the participants are performing a memory task, or when lying at rest. Subjects will undergo a brain scan under both of these conditions after a dose of either the study drug or a placebo is administered.

Condition Intervention Phase
Drug: Placebo
Drug: PF-04958242
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Subject And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, Parallel Group Study To Assess Effects Of PF-04958242 On Bold Functional MRI During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • functional magnetic resonance imaging data during working memory task [ Time Frame: 40 minutes post-dose ]
  • Arterial spin labeling data [ Time Frame: 50 minutes post-dose ]

Enrollment: 112
Study Start Date: June 2011
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
oral solution, single dose
Experimental: PF-04958242 - 0.075mg Drug: PF-04958242
oral solution, single dose; 0.075mg
Experimental: PF-04958242 - 0.15mg Drug: PF-04958242
oral solution, single dose; 0.15mg


Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male and/or female subjects of non-childbearing potential between the ages of 21 and 55 years, inclusive
  • Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)

Exclusion Criteria:

  • History of seizures or of a condition with risk of seizures; head injury; any history of DSM-IV Axis I psychiatric disorders; contraindications for MRI
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01365338

United States, Connecticut
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511
Pfizer Investigational Site
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT01365338     History of Changes
Other Study ID Numbers: B1701003
Study First Received: May 11, 2011
Last Updated: December 21, 2012

Keywords provided by Pfizer:
schizophrenia fMRI cognition working memory ASL

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders processed this record on April 25, 2017